<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00202839</url>
  </required_header>
  <id_info>
    <org_study_id>P04144</org_study_id>
    <nct_id>NCT00202839</nct_id>
  </id_info>
  <brief_title>Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED)</brief_title>
  <official_title>Comparison of the Sustained Response of Peg-Intron/Ribavirin Combination Therapy in Genotype 1-Infected Hepatitis C Patients for Non-extended Versus 24-week Extended Treatment After 24 Weeks Pilot Treatment in Taiwan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>Taiwan: Department of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, randomized, comparative, multicenter, 48-week study designed to
      evaluate the efficacy and safety of combination treatment with pegylated interferon and
      ribavirin in adult subjects with a diagnosis of compensated chronic hepatitis C (hepatitis C
      virus (HCV)-ribonucleic acid (RNA) positive) (Genotype 1). All subjects will complete 24
      weeks of treatment, termed the Pilot Treatment Program, after which all eligible subjects
      will be randomly assigned to one of two study groups. One group will be followed for an
      additional 48 weeks without study medication, while the other will be continuously treated
      for an additional 24 weeks and then followed for another 24 weeks without study medication.
      Sustained virologic response, defined as undetectable HCV-RNA in serum at the end of the
      follow-up period, will be measured along with other outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, randomized, comparative, multicenter study for evaluation of
      PegIntron/Ribavirin therapy in the efficacy and safety in adult subjects with a diagnosis of
      compensated chronic hepatitis C (HCV-RNA+) (Genotype 1). This is a 48-week study, for which
      all subjects should participate in the Pilot Treatment Program and complete 24 weeks
      treatment. To avoid a treatment gap, subjects who will be screened and eligible subjects
      will sign informed consent prior to the end of the Pilot Treatment Program. After completion
      of the Pilot Treatment Program, all eligible subjects will be randomly assigned to either
      study group. Subjects in the 24-Week Treatment arm will be followed-up without study
      medication for 48 weeks; subjects in the 48-Week Treatment arm will be continuously treated
      for another 24 weeks and all subjects in the 48-Week Treatment arm will be followed for
      another 24 weeks after completion of the treatment period. Subjects in both arms will be
      evaluated at screening, randomization, 4, 8, 12, 16, 20, 24, 28, 36 and 48 weeks after
      randomization.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The Percentage of Participants Who Achieved a Sustained Virologic Response (SVR)</measure>
    <time_frame>24 weeks of follow-up after either 24 or 48 weeks of anti-HCV therapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>Sustained virologic response was defined as hepatitis C virus ribonucleic acid [HCV-RNA] levels below assay detection 24 weeks after termination of anti-HCV therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Participants Who Achieved a Virologic Response 48 Weeks After Randomization.</measure>
    <time_frame>48 weeks after randomization (with 24 weeks of treatment immediately before randomization and either 0 or 24 weeks of treatment immediately after randomization)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Virologic response was defined as undetectable HCV-RNA level in the blood.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>24-Week Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Genotype 1 hepatitis C virus [HCV] subjects treated for a total of 24 weeks, during the pilot treatment program (immediately before randomization)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>48-Week Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Genotype 1 HCV subjects treated for a total of 48 weeks: 24 weeks during the pilot treatment program (immediately before randomization) plus 24 weeks during the extended treatment program (immediately after randomization)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PegIntron (peginterferon alfa-2b; SCH 54031)</intervention_name>
    <description>Powder for injection in vial (120 microgram strength), subcutaneous, dose of 1.5 micrograms/kg weekly for 24 weeks during the pilot treatment program</description>
    <arm_group_label>24-Week Treatment</arm_group_label>
    <other_name>peginterferon alfa-2b; SCH 54031</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PegIntron (peginterferon alfa-2b; SCH 54031)</intervention_name>
    <description>Powder for injection in vial (120 microgram strength), subcutaneous, dose of 1.5 micrograms/kg weekly for 24 weeks during the pilot treatment program followed by 1.2 to 1.5 microgram/kg weekly for 24 weeks during the extended treatment program</description>
    <arm_group_label>48-Week Treatment</arm_group_label>
    <other_name>peginterferon alfa-2b; SCH 54031</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>200 mg capsules, oral, weight-based dose of 1000 or 1200 mg, daily for for 24 weeks during the pilot treatment program</description>
    <arm_group_label>24-Week Treatment</arm_group_label>
    <other_name>SCH 18908</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>200 mg capsules, oral, weight-based dose of 1000 or 1200 mg, daily for for 24 weeks during the pilot treatment program and for 24 weeks during the extended treatment program</description>
    <arm_group_label>48-Week Treatment</arm_group_label>
    <other_name>SCH 18908</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must be willing to give written informed consent and be able to adhere to
             dose and visit schedules.

          -  Males and non-pregnant females and aged &gt;= 18 years, subjects who are over 65 years
             of age must be in generally good health and must be discussed with and approved by
             the principal investigator prior to entry.

          -  The laboratory evaluation within 6 months prior to entering the Pilot Treatment
             Program must meet the following criteria:

          -  Hemoglobin values of &gt;= 12 g/dL for females and &gt;= 13 g/dL for males

          -  Neutrophil count &gt;= 1.5 X10^9/L

          -  Platelets count &gt;= 100 x 10^9/L

          -  Total bilirubin &lt; 1.5 mg/dL

          -  Serum creatinine within normal limits

          -  Positive serum HCV-RNA (&gt;= 50 IU (100 copy numbers)/mL)

          -  Anti-HCV positive

          -  Available HCV genotype 1

          -  Liver biopsy performed within 12 months prior to entry to this protocol with a
             pathology report confirming that the histological diagnosis is consistent with
             chronic hepatitis (METAVIR system &gt;=F1).

          -  Compensated liver disease with the following hematological, biochemical, and
             serologic criteria at the screening visit:

          -  Hemoglobin values of &gt;= 9 g/dL

          -  Neutrophil count &gt;= 0.75 x 10^9/L

          -  Platelets count &gt;= 50 x 10^9/L

          -  Prothrombin time (PT) prolong &lt;= 3 sec, International Normalized Ratio (INR) &lt;= 1.2

          -  Total bilirubin &lt;= 3 mg/dL

          -  Within normal limits (subjects requiring medication to maintain TSH levels in the
             normal range are eligible if all other inclusion/exclusion criteria are met).

          -  Anti-Human Immunodeficiency Virus (HIV) negative.

          -  Alpha-fetoprotein (AFP) value within normal limits obtained within 12 months prior to
             entry. Results above the upper limit of normal but &lt;= 50 ng/mL require both of the
             following:

          -  AFP value &lt;= 50 ng/mL obtained within 9 months prior to entry in the study or during
             the Screening period, and Ultrasound obtained within 9 months prior to entry or in
             the screening period in the study for evidence of not having hepatocellular
             carcinoma.

          -  A urine pregnancy test obtained prior to the initiation of pilot treatment must be
             negative. Female subjects must not be breast feeding.

          -  Reconfirmation that sexually-active subjects are practicing acceptable methods of
             contraception during screening period.

          -  Complete 24 weeks treatment of the Pilot Treatment Program with Peg-Intron +
             Ribavirin.

          -  Must be never treated with interferon for HCV infected hepatitis (treatment na√Øve)
             before the Pilot Treatment Program.

          -  The total amount of Peg-Intron and Ribavirin received during the pilot treatment
             program must achieve more than 80% of the recommended dosage.

        Exclusion Criteria:

          -  Women who are pregnant or nursing.

          -  Have decompensated cirrhosis.

          -  History of severe psychiatric disease, especially depression.

          -  Concurrent malignancies (including hepatocellular carcinoma).

          -  Unstable or significant cardiovascular diseases. Subjects with (ECG) showing
             clinically significant abnormalities.

          -  Prolonged exposure to known hepatotoxins such as alcohol or drugs.

          -  History of thyroid disease poorly controlled on prescribed medication.

          -  Poorly controlled diabetes mellitus.

          -  Has suspected or confirmed significant hepatic disease from an etiology other than
             HCV.

          -  Patients co-infected with hepatitis B and /or human immunodeficiency virus (HIV).

          -  Severe renal disease or myeloid dysfunction.

          -  History of organ transplantation other than cornea and hair transplant.

          -  Any medical condition requiring, or likely to require during the course of the study,
             chronic systemic administration of steroids.

          -  Any other condition which in the opinion of the investigator would make the subject
             unsuitable for enrollment, or could interfere with the subject participating in and
             completing the protocol.

          -  Allergy to interferon.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ding-Shinn Chen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Investigational Site</affiliation>
  </overall_official>
  <removed_countries>
    <country>Taiwan</country>
  </removed_countries>
  <verification_date>April 2015</verification_date>
  <lastchanged_date>April 7, 2015</lastchanged_date>
  <firstreceived_date>September 12, 2005</firstreceived_date>
  <firstreceived_results_date>August 28, 2009</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results are available for this study                                           -->
</clinical_study>
